Please note: This review reflects information we gathered on the date it was researched and may now be out of date. Providers frequently change their pricing, plans, medications, and policies. Any ratings, reviews, and customer feedback are gathered from publicly available online sources and may have since changed or no longer be accurate. Always do your own research and confirm the latest details directly with the provider before making any decision.
HealthRX Review
The most informative document we found about this company was its affiliate commission schedule. So we are publishing all of it.
HealthRX
We're Paid $0 To Let You TryThe commission ladder is the story: "1 Month Plans: $0.00". "Existing Customers: $0.00". Then sermorelin pays $145.83 at three months, $279.17 at six and $520.83 at twelve. Everyone writing about this company for money is on that curve — paid nothing to suggest you try a month, and the most to lock you in for a year.
And it runs inverse to the evidence: a year of sermorelin — no long-term human outcome trials — pays $520.83. A year of GLP-1 treatment, backed by large randomised trials, pays $250. More than double, for the weaker evidence. At the listed $179/mo, our cut of a 12-month sermorelin plan is about 24% of everything that patient pays.
Their "honest math" benchmarks an obsolete price: the homepage cites "Brand-name GLP-1 (retail) $1,000+/mo". True as a list price, but NovoCare now lists the FDA-approved Wegovy pill at $149/mo and the pen at $199, and LillyDirect lists Zepbound vials from $299 — none of which appear in the comparison.
In fairness: they publish a LegitScript certificate number (50087439) rather than a vague badge, disclose "Compounded 503A" plainly, reference FDA status repeatedly rather than dodging it, promise a full refund if a provider does not approve you, and publish per-product pricing by plan length. Three-month plans exist. Compounded GLP-1s run $99 to $249/mo.
Affiliate disclosure — the whole schedule: 1 month $0 · existing customers $0 · ED $54.17/$112.50/$220.83 · nasal NAD+ $70.83/$137.50/$250 · PT-141 $108.33/$208.33/$387.50 · NAD+ injection $125/$237.50/$445.83 · sermorelin $145.83/$279.17/$520.83 · GLP-1 $208 at 3 months, $250 at 6 or 12. We publish it in full because it predicts what every paid review of this company will tell you. Verified 8 August 2026.
Visit HealthRXOur Top Recommended Provider: CoreAge Rx
After reviewing dozens of GLP-1 telehealth providers, CoreAge Rx is the one we recommend most. CoreAge Rx is one of our partners — read on for why we recommend them:
Flat-Rate Pricing
Same cost at every dose level — no price jumps as you titrate up.
Verified Pharmacies
US-licensed physicians and NABP-verified 503A compounding pharmacies you can trust.
Everything Included
Medication, supplies, free shipping, and ongoing clinical support — no hidden fees.
Active Community of Members
Ask questions, share progress, and get answers from other patients on the same journey — alongside ongoing clinical support from your care team.
$0
Our Fee If You Try One Month
$520.83
Our Fee For A Year Of Sermorelin
$250
Our Fee For A Year Of GLP-1s
~24%
Our Cut Of Your Annual Spend
What We Verified
Prices from HealthRX's own pages, comparators from the two manufacturers' own self-pay pages the same day, and the commission ladder from the programme terms we are working under.
We Are Paid Nothing To Let You Try It
The commission schedule reads "1 Month Plans: $0.00" and "Existing Customers: $0.00". Every rung above that rewards length: sermorelin pays $145.83 at three months, $279.17 at six and $520.83 at twelve. An affiliate who wants to be paid has to sell you a year
And Paid Most For The Product With Least Evidence
A 12-month sermorelin plan pays $520.83. A 6 or 12-month GLP-1 plan pays $250. So this programme pays us more than twice as much to sell a year of a peptide with no long-term outcome trials as to sell a year of a medicine backed by large randomised trials
That Commission Is About A Quarter Of What You Pay
Sermorelin is listed "from $179/mo". Twelve months at that rate is roughly $2,148, of which our $520.83 is about 24%. NAD+ injection from $161/mo works out near $1,932 a year against a $445.83 payout, or about 23%. Customer acquisition costing a quarter of first-year revenue tells you something about the margins
"The Honest Math" Compares Against An Obsolete Price
Their homepage runs a section headed "The honest math" citing "Brand-name GLP-1 (retail) $1,000+/mo — Wegovy or Zepbound list price without insurance". That list price is real, but it is no longer the relevant alternative: NovoCare and LillyDirect now sell direct to self-paying patients, and neither appears in the comparison
The Real Comparison, Checked The Same Day
NovoCare listed the FDA-approved Wegovy pill at $149/mo and the pen at $199/mo for new self-pay patients; LillyDirect listed Zepbound vials from $299. HealthRX's own compounded prices run $99 to $249. That is a much narrower gap than $1,000-plus implies, and the approved product is the reviewed one
There Are Real Credentials Here Too
The site displays LegitScript certification number 50087439, states evaluations are by US board-certified physicians, discloses "Compounded 503A", and promises "If a licensed provider doesn't approve you, you get a full refund". We could not confirm the certificate through LegitScript's public search tool, but the number is published and checkable
The Ladder, In Full
What an affiliate earns for sending you here, by product and commitment length. Published because it predicts what you will read elsewhere.
| Product | 3 Months | 6 Months | 12 Months |
|---|---|---|---|
| Sermorelin | $145.83 | $279.17 | $520.83 |
| NAD+ injection | $125.00 | $237.50 | $445.83 |
| PT-141 | $108.33 | $208.33 | $387.50 |
| NAD+ nasal | $70.83 | $137.50 | $250.00 |
| Erectile dysfunction | $54.17 | $112.50 | $220.83 |
| GLP-1s | $208.00 | $250.00 | $250.00 |
| One month, or an existing customer | $0.00 — nothing, on any product | ||
The bottom row is the one to sit with. Nobody earns anything by helping you test whether something suits you, and nobody earns anything from you staying a happy customer. All of the money is in the length of the initial commitment.
What You Pay Versus What We Take
Prices from their own pages on 8 August 2026. Annual figures and percentages are our arithmetic.
| 12-Month Plan | Listed Price | You Pay, Roughly | We Take |
|---|---|---|---|
| Sermorelin | From $179/mo | ~$2,148 | $520.83 — about 24% |
| NAD+ injection | From $161/mo | ~$1,932 | $445.83 — about 23% |
| NAD+ nasal spray | From $134/mo | ~$1,608 | $250 — about 16% |
| Compounded GLP-1 | $99–$249/mo | Varies by dose and plan | $250 — the lowest rung |
Before any of this, price the FDA-approved options: NovoCare listed the Wegovy pill at $149/mo and the pen at $199/mo the same day, and LillyDirect listed Zepbound vials from $299. Our Luvo Health review sets out why we are sceptical of sermorelin and NAD+ as longevity purchases at all, and our cost guide covers insurance routes that beat every cash price here.
Pros & Cons
Pros
- ✓A published LegitScript certification number, 50087439, which is a real credential in telehealth and is checkable
- ✓Full refund if a licensed provider does not approve you, stated up front
- ✓"Compounded 503A" disclosed plainly rather than buried, with FDA referenced repeatedly on the site
- ✓Evaluations described as being by US board-certified physicians, with all 50 states served
- ✓Upfront per-product pricing published by plan length, so you can do the arithmetic yourself
- ✓Free overnight shipping and a stated 3 to 5 days from prescription to delivery
- ✓Compounded GLP-1 prices of $99 to $249 genuinely undercut the brand list price
- ✓Shorter three-month plans exist, so a year is not the only option even though it is the only one that pays us
Cons
- ✕The commission ladder pays $0 on one-month plans and $520.83 at twelve months, which is an incentive to sell length rather than fit
- ✕Sermorelin at 12 months pays us more than double what a year of GLP-1 treatment pays
- ✕Our commission on a 12-month sermorelin plan is roughly 24% of what the patient spends that year
- ✕Nothing is paid on existing customers, so every incentive points at new sign-ups rather than continuity of care
- ✕"The honest math" omits the manufacturers' own direct self-pay pricing, which is the comparison that now matters
- ✕Sermorelin and NAD+ carry no long-term human outcome trials for healthspan at roughly $1,600 to $2,148 a year
- ✕Compounded medicines are not FDA-approved and are not reviewed for safety, efficacy or quality
- ✕PT-141 is sold for sexual health; bremelanotide is an approved drug, and a compounded version is not that product
- ✕We could not confirm the LegitScript certificate through the public search tool, only that a number is displayed
- ✕A 4.8 rating from "12,000+ members" is self-reported on the company's own site
Our Verdict
2.5 / 5 — a credentialed operation running a commission structure engineered against the customer's interest.
The most revealing document we found about HealthRX was not on its website. It was the affiliate commission schedule we are working under, and it is worth reading in full because it tells you what every paid review of this company is being paid to say. One-month plans: $0.00. Existing customers: $0.00. Then the ladder climbs with commitment length. Erectile dysfunction pays $54.17, $112.50 and $220.83 at three, six and twelve months. Nasal NAD+ pays $70.83, $137.50 and $250. PT-141 pays $108.33, $208.33 and $387.50. NAD+ injection pays $125, $237.50 and $445.83. Sermorelin pays $145.83, $279.17 and $520.83. GLP-1s pay $208 at three months and $250 at six or twelve. Sit with the two zeroes at the top. Nobody earns anything for suggesting you try a single month to see whether something suits you, and nobody earns anything from you being an existing, satisfied customer. The entire economics of the referral ecosystem around this company sit in the length of your initial commitment, on products you cannot easily un-buy.
Worse than the shape of the ladder is its ordering. A twelve-month GLP-1 plan pays $250. A twelve-month sermorelin plan pays $520.83. GLP-1 receptor agonists for weight management are supported by large randomised controlled trials and exist as FDA-approved products with characterised benefits and risks. Sermorelin is a growth hormone-releasing hormone analogue sold for longevity, with no long-term human outcome trials demonstrating benefit or harm. This programme pays more than twice as much for a year of the second as for a year of the first, and NAD+ injection at $445.83 also outranks the GLP-1 rate. We do not think anyone deliberately ranked the catalogue by weakness of evidence; the likelier explanation is that peptide subscriptions carry fatter margins and longer tenure, so they can afford richer payouts. But the consequence for a reader searching for reviews is identical either way, and it is why we have put the whole table on this page rather than a line of small print at the bottom.
Set the payouts against the prices and the scale becomes clearer. Their longevity pages list sermorelin "from $179/mo", NAD+ injection at 1,000 mg per month "from $161/mo" and nasal NAD+ spray "from $134/mo", with an FAQ noting pricing "starts from about $149/month and varies by medication and plan length". Annualised at those rates, a year of sermorelin is roughly $2,148 and a year of NAD+ injection roughly $1,932. Our $520.83 is therefore about 24% of everything that sermorelin patient spends in their first year, and the NAD+ figure is about 23%. A business paying roughly a quarter of first-year revenue to acquire a customer is not doing anything improper — acquisition is genuinely expensive in this sector — but it does tell you something useful about where the $179 goes, and it is worth knowing while someone is explaining that the price reflects pharmaceutical quality.
The other substantive criticism concerns a section on their homepage headed "The honest math". It presents three tiers: "Brand-name GLP-1 (retail) $1,000+/mo — Wegovy or Zepbound list price without insurance", then "Other online GLP-1 clinics $199 to $249/mo", then their own pricing. The first figure is not false; list prices really are there, and for years that is what pushed people towards compounded alternatives. What is missing is that both manufacturers now sell directly to self-paying patients. On the same day we read that page, NovoCare listed the FDA-approved Wegovy pill at $149 a month and the pen at $199 for new self-paying patients, and LillyDirect listed Zepbound vials from $299. Neither appears in the comparison. Benchmarking against the least favourable brand price while omitting the manufacturers' own programmes is persuasion rather than arithmetic, and the heading makes it harder to excuse rather than easier. The underlying point matters beyond this company: compounded means not FDA-approved, the agency reviews these products for neither safety nor effectiveness nor quality, and the price gap that once justified accepting that trade-off has narrowed dramatically.
To be fair, there is a real operation here. HealthRX publishes a LegitScript certificate number, 50087439, rather than an unfalsifiable trust badge — we could not confirm it through LegitScript's public search tool and report that as a limitation rather than a finding, but publishing a checkable number is the right instinct. The site discloses "Compounded 503A" plainly, references FDA status repeatedly instead of avoiding the topic, states that evaluations are by US board-certified physicians, and promises a full refund if a provider does not approve you, which removes a real risk. Prices are published per product and per plan length. Three-month plans exist. None of that is nothing, and it is why this is a 2.5 rather than something lower. So the advice. Price the FDA-approved options before any compounded route. If you proceed, take the shortest plan available, which is precisely the one nobody is paid to sell you. Before anything acting on the growth hormone axis, get baseline bloods including IGF-1 through your own clinician. Check insurance and your employer's formulary first, because coverage beats every cash price discussed here. And treat every enthusiastic review of this company in light of the table above — including this one, which earns us up to $520.83 and will earn us nothing at all if you follow a word of this paragraph.
Visit HealthRXFrequently Asked Questions
Why are you leading with your own commission?
Because in this case the commission schedule is the most informative document we found, and it says more about the business model than any marketing page does. Here is the whole ladder, as published to affiliates. One-month plans: $0.00. Existing customers: $0.00. Non-GLP default: $0.00. Then it climbs by commitment length. Erectile dysfunction: $54.17 at three months, $112.50 at six, $220.83 at twelve. Nasal NAD+: $70.83, $137.50, $250. PT-141: $108.33, $208.33, $387.50. NAD+ injection: $125, $237.50, $445.83. Sermorelin: $145.83, $279.17, $520.83. GLP-1s: $208 at three months, $250 at six or twelve. Read that structure rather than the individual numbers. An affiliate earns literally nothing for sending you to try a single month, and $520.83 for signing you to a year of sermorelin. Everyone writing about this company online is being paid on exactly that curve, which means the entire incentive of the review ecosystem around HealthRX points towards the longest possible prepaid commitment on the least reversible products. We think you should know that before you read anybody's recommendation, including ours. It is also worth noticing that the schedule pays $0.00 on existing customers, so the money is entirely in acquisition rather than in anyone staying well or staying happy.
What does the ladder say about which products they push?
That the payout runs inverse to the evidence, which is the finding that decided this rating. Compare two rungs directly. A 6 or 12-month GLP-1 plan pays an affiliate $250. A 12-month sermorelin plan pays $520.83. GLP-1 receptor agonists for weight management are supported by large randomised controlled trials, are available as FDA-approved products, and have well-characterised benefits and risks. Sermorelin is a growth hormone-releasing hormone analogue sold for longevity, with no long-term human outcome trials showing it extends healthspan or lifespan in either direction. This programme pays more than twice as much to sell a year of the second than a year of the first. NAD+ injection at twelve months pays $445.83, also well above the GLP-1 rate. We are not suggesting anyone at the company sat down and ranked products by weakness of evidence. The likelier explanation is simple economics: peptide subscriptions carry higher margins and longer expected tenure than GLP-1 plans, so they can afford to pay more for them. But the effect on what you will read online is the same either way. If you search for reviews of this company, the pages you find will have been written by people paid $520.83 for a sermorelin signup and $0 for suggesting you try one month first. Our own view of the underlying science is set out in our review of another provider selling the same two molecules, and it has not changed here.
How much does it actually cost?
Roughly $1,600 to $2,150 a year for the longevity products, and $99 to $249 a month for the GLP-1s. From their longevity pages, checked on 8 August 2026: sermorelin "Subscribe from $179/mo", NAD+ injection at 1,000 mg per month "from $161/mo", and nasal NAD+ spray at 300 mg/ml in a 15 ml bottle "from $134/mo", with the FAQ stating that "Pricing starts from about $149/month and varies by medication and plan length". Note the word from — those are the rates before plan length is applied, and the longer commitments are presumably where the lower per-month figures live. Annualised at the quoted rates, sermorelin is about $2,148 a year and NAD+ injection about $1,932. On the weight-loss side their homepage cites compounded prices between $99 and $249 a month. Set the commission against those numbers and the picture sharpens: our $520.83 for a 12-month sermorelin plan is about 24% of the roughly $2,148 that patient pays across the year, and the $445.83 NAD+ injection payout is about 23% of $1,932. A business paying out roughly a quarter of first-year revenue to acquire a customer is telling you, indirectly, what the gross margin on compounded peptides looks like. That is not an accusation of anything improper — customer acquisition is expensive in this sector — but it is context worth having when you are deciding whether $179 a month represents the cost of making the medicine or the cost of selling it to you.
What is wrong with their price comparison?
It benchmarks against a price almost nobody needs to pay any more, in a section headed "The honest math". The homepage sets out three tiers: "Brand-name GLP-1 (retail) $1,000+/mo — Wegovy or Zepbound list price without insurance", then "Other online GLP-1 clinics $199 to $249/mo", then their own pricing. The first line is not false. List prices without insurance really are in that range, and for years that was the number that drove people to compounded alternatives. What has changed is that both manufacturers now sell directly to self-paying patients, and neither route appears in the comparison. Checked the same day we read their page: NovoCare listed the FDA-approved Wegovy pill at $149 a month for the 1.5mg or 4mg doses and the Wegovy pen at $199 a month for new self-paying patients through 31 December 2026; LillyDirect listed Zepbound single-dose vials from $299 for 2.5mg, $399 for 5mg and $449 for 7.5mg through 15mg when refilled within 45 days. Against those numbers the gap between compounded and approved is a fraction of what "$1,000+/mo" implies, and in the case of Wegovy it can run the other way. A comparison table that presents the least favourable brand price and omits the manufacturers' own programmes is doing persuasion rather than arithmetic, and putting it under the heading "the honest math" makes that worse rather than better. Price the approved routes yourself before you accept any clinic's framing of what the alternative costs.
Are the credentials real?
Partly verified, and we will be precise about which parts. The site displays "LegitScript · Cert. 50087439". LegitScript certification is a genuine and meaningful credential in this sector — it is the standard the major advertising platforms require before they will accept healthcare advertising, and it involves review of licensure, pharmacy relationships and business practices. Displaying a specific certificate number rather than a vague badge is the right way to make the claim, because it is checkable. We tried to check it: LegitScript's public website search returned a page for our query but did not surface a result we could read as confirming or denying the certification, so we are reporting that we could not verify it through that tool rather than that it is false. Readers who want certainty can search the number directly at legitscript.com. The other claims on the page are the usual ones and we have not independently verified any of them: evaluations by US board-certified physicians, service in all 50 states, HIPAA compliance, free overnight shipping, and delivery in three to five days from prescription. The refund promise is unusually clear and worth noting in their favour — "If a licensed provider doesn't approve you, you get a full refund" removes the risk of paying for a consultation that goes nowhere. The 4.8 rating from "12,000+ members" is self-reported on their own site and should be treated as marketing rather than as independent evidence.
Should I buy sermorelin or NAD+ from anyone?
Not on the evidence currently available, and certainly not on a twelve-month prepayment. We looked at this question in detail when reviewing another provider selling the same two molecules, and the conclusion applies here unchanged. On sermorelin, the commercial logic is that growth hormone falls with age so restoring it should help. The difficulty is that ageing research points substantially the other way: reduced growth hormone and IGF-1 signalling is associated with longer life across model organisms, humans with growth hormone receptor deficiency have been reported to show strikingly low rates of cancer and diabetes, and higher circulating IGF-1 has been linked observationally to several cancers. Sermorelin prompts pulsatile release rather than flooding the system with exogenous hormone, effects are modest, and crucially there are no long-term human outcome trials in either direction — so this is a reason for caution rather than a finding of harm. On NAD+, the molecule is genuinely central to cellular metabolism and levels do change with age, but raising a biomarker is not the same as improving an outcome, and no clinical longevity benefit has been established. Selling the same nominal compound as injection at $161 and nasal spray at $134 also invites a question about how much actually reaches circulation by each route. If you want to explore either, the sensible approach is the shortest plan available, baseline and follow-up bloods through your own clinician including IGF-1 for anything acting on the growth hormone axis, and a clear conversation about what would make you stop. What you should not do is prepay a year — which is, not coincidentally, the only version of this purchase that pays us anything.
Does any of this apply if I just want a GLP-1?
Yes, in three ways. First, price the FDA-approved options before the compounded ones. That advice would have been wrong two years ago and is right now: NovoCare and LillyDirect both sell direct to self-paying patients, and as of 8 August 2026 the approved Wegovy pill at $149 a month sits inside the range this clinic charges for a compounded copy. Compounded means not FDA-approved — the agency reviews it for neither safety, effectiveness nor quality — so if the prices are comparable, the choice is not difficult. Second, understand the regulatory clock. FDA declared the tirzepatide shortage resolved on 19 December 2024 and semaglutide on 21 February 2025, closing the shortage pathway that justified mass compounding, and on 30 April 2026 proposed excluding both molecules from the 503B bulks list, with comments closing 30 July 2026. Lawful compounding lanes remain and we make no allegation about this company, but a treatment you may want for years deserves that context. Third, and specific to this provider: the GLP-1 rungs on the commission ladder are the lowest ones. If you go to HealthRX for a GLP-1 and are steered towards adding sermorelin or NAD+, notice that the second conversation is worth roughly twice as much to whoever referred you. That does not make the suggestion wrong, but it is the kind of thing worth knowing while you are being made the offer. Check your insurance and your employer's formulary first, because coverage beats every cash price discussed here.
What is your verdict?
2.5 out of 5 — a credentialed operation running a commission structure engineered against the customer's interest. The positives are real and we will not bury them. HealthRX publishes a LegitScript certificate number rather than a vague trust badge, discloses "Compounded 503A" plainly, references FDA status repeatedly rather than avoiding the subject, promises a full refund if a provider does not approve you, publishes per-product pricing by plan length so you can do your own arithmetic, and offers three-month plans rather than forcing an annual commitment. Its compounded GLP-1 pricing of $99 to $249 a month is genuinely below brand list prices. Now the reasons for the rating, and the first is unusual because it concerns us rather than them. The affiliate schedule pays $0.00 on one-month plans, $0.00 on existing customers, and then climbs steeply with commitment: sermorelin at $145.83, $279.17 and $520.83 for three, six and twelve months. Every person writing about this company for money is on that curve, which means the whole review ecosystem around it is paid to sell length. Worse, the ladder runs inverse to the evidence — a year of sermorelin pays $520.83 while a year of GLP-1 treatment pays $250, so the payout is more than double for the product with no long-term outcome trials. At a listed $179 a month, our commission on that annual sermorelin plan is roughly 24% of what the patient spends. Add a homepage section headed "The honest math" that benchmarks against "$1,000+/mo" brand list pricing while omitting NovoCare at $149 to $199 and LillyDirect from $299, and the pattern is a company whose disclosures are decent and whose framing is not. Our recommendation: price the approved options first, take the shortest plan if you proceed at all, get your own baseline bloods before anything acting on the growth hormone axis, and treat every enthusiastic review of this company — ours included — in light of the ladder we have just published. Our disclosure: up to $520.83 per conversion, and $0.00 if you follow the advice in this paragraph.
Take The Shortest Plan.
It is the one nobody is paid to sell you — one month earns every affiliate exactly $0. Price the FDA-approved options first, and get baseline bloods before anything touching the growth hormone axis.
Visit HealthRXCompare Other GLP-1 Providers
See how other telehealth providers stack up.
CoreAge Rx
#1 RecommendedFlat-rate pricing for compounded semaglutide and tirzepatide with NABP-verified pharmacies
Read Review →GoodRx Care
Trusted BrandTelehealth platform from GoodRx with transparent pricing and established trust
Read Review →Boston Medical Group
Top RatedEstablished telehealth provider with physician oversight and transparent pricing
Read Review →Mochi Health
Obesity Medicine SpecialistsBoard-certified obesity medicine specialists with both brand-name and compounded GLP-1 options
Read Review →Alan Meds
Top RatedAffordable compounded GLP-1s with board-certified physicians and straightforward pricing
Read Review →Henry Meds
Top RatedWell-established telehealth platform with fast physician reviews and competitive pricing
Read Review →Medical Disclaimer: This page is informational and is not medical advice, a diagnosis, or a recommendation for or against any treatment or provider. Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness or quality. GLP-1 receptor agonists are prescription medicines with serious potential risks; in animal studies semaglutide and tirzepatide caused thyroid C-cell tumours, and they are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Reported adverse effects include pancreatitis, gallbladder disease, kidney injury, severe gastrointestinal effects and, through delayed gastric emptying, risks relating to anaesthesia. Sermorelin acts on the growth hormone axis and is not appropriate for everyone; it may be contraindicated in active malignancy, and anyone with a personal or family history of cancer should raise that specifically with a clinician. Statements about associations between growth hormone or IGF-1 signalling and longevity or cancer risk are general summaries of a literature drawn largely from model organisms and observational human studies; associations are not causation and nothing here establishes that any product is beneficial or harmful. PT-141 is sold here for sexual health; bremelanotide is an approved medicine for a specific indication in premenopausal women and a compounded preparation is not that approved product. Only a licensed clinician with your full history can determine whether any of these treatments is appropriate. Do not start, stop or change any prescribed medication on the basis of this page. Prices quoted are the sellers' published figures on the date stated, are subject to eligibility conditions, and change without notice. Consult a licensed clinician before starting or changing any treatment.
Date reviewed: 8 August 2026. Commission figures are reproduced in full from the affiliate programme terms for Katalys offer #1630 as presented to us, which list: Non-GLP default $0.00; 1 Month Plans $0.00; Existing Customers $0.00; Sermorelin 3mo $145.83, 6mo $279.17, 12mo $520.83; NAD+ (injection) 3mo $125.00, 6mo $237.50, 12mo $445.83; NAD+ (nasal) 3mo $70.83, 6mo $137.50, 12mo $250.00; PT-141 3mo $108.33, 6mo $208.33, 12mo $387.50; ED 3mo $54.17, 6mo $112.50, 12mo $220.83; GLP 3 Month $208.00; GLP 6 and 12 Month $250.00; Cookie Window $0.00. HealthRX prices were read from healthrx.com on the same date: the longevity category page listed sermorelin 'Subscribe from $179 /mo' with the claims 'Prompts your own GH', 'Preserves pulsatile release' and 'At-home injection'; 'NAD+ Injection 1,000 mg per month' from $161/mo; and 'NAD+ Nasal Spray 300 mg/ml, 15 ml bottle' from $134/mo, with an FAQ stating 'Pricing starts from about $149/month and varies by medication and plan length' and a page note of '$149/mo starting price, before plan length'. The homepage displayed 'Compounded GLP-1 prescription medication delivered to your door', 'Compounded 503A · Ships in 24-48h', 'Evaluations by US Board-certified physicians', 'No insurance needed. If a licensed provider doesn't approve you, you get a full refund', 'Upfront pricing, no hidden fees', 'HIPAA Compliant', 'Free overnight shipping · All 50 states', a self-reported rating of '4.8 · 12,000+ members', and 'LegitScript · Cert. 50087439'. It also carried a section headed 'The honest math' reading 'Same medication class. Three very different prices.' with tiers of 'Brand-name GLP-1 (retail) $1,000+/mo — Wegovy or Zepbound list price without insurance' and 'Other online GLP-1 clinics $199 to $249/mo'; prices appearing on that page included $99, $133, $179, $199, $209 and $249. Annualised figures (~$2,148 for sermorelin, ~$1,932 for NAD+ injection, ~$1,608 for nasal NAD+) and the resulting commission percentages of approximately 24%, 23% and 16% are our own arithmetic from the listed monthly 'from' rates multiplied by twelve, and actual charges may differ by plan and dose. Comparator prices were read the same day from the manufacturers' own self-pay pages: NovoCare listed the Wegovy pill at $149 per month for the 1.5 mg or 4 mg doses and the Wegovy pen at $199 per month for new self-paying patients as a limited-time offer through 31 December 2026; LillyDirect listed Zepbound single-dose vials starting at $299/month for 2.5 mg, $399 for 5 mg and $449 for 7.5 mg through 15 mg when refilled within 45 days, with regular prices of $499 to $699 outside that window. Regulatory background: FDA declared the tirzepatide shortage resolved on 19 December 2024 and semaglutide on 21 February 2025; challenges by the Outsourcing Facilities Association did not secure preliminary injunctions; and on 30 April 2026 FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list, with comments closing 30 July 2026. That is general consumer context and is not an allegation that HealthRX or any pharmacy it works with has breached any law or regulation. Limitations: we attempted to verify LegitScript certificate 50087439 through LegitScript's public website search and could not retrieve a result we could read as confirming or denying it; we report that as an unverified claim rather than a false one, and readers can check the number directly at legitscript.com. We did not create an account, complete an intake, consult a clinician, receive any medication or test the refund or cancellation process, and we make no independent assessment of clinical quality, prescriber licensure coverage, shipping or customer service. The 4.8 rating and '12,000+ members' figure are self-reported by the company on its own site.
Affiliate Disclosure: This site may receive compensation from affiliate partners. This programme's full commission schedule is reproduced in the body of this review rather than summarised here, because we believe its structure — $0.00 for one-month plans and for existing customers, rising to $520.83 for a twelve-month sermorelin commitment — is material information for anyone reading any review of this company, ours included. Our recommendations here are to price the FDA-approved options first, to take the shortest plan available, and to obtain independent baseline bloods, all of which reduce or eliminate what we earn. This does not influence our editorial content or review ratings.